ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesity
On 28 March, at the American College of Cardiology (ACC) 75th Annual Scientific Session & Expo in New Orleans, Louisiana,…
Metabolic Disorders
-
-
ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D
Type 2 diabetes (T2D) and heart health have a complex and dependent relationship. New data presented at ACC 2026 suggests…
-
Novo sues Hims & Hers despite Wegovy pill offering U-turn
Hims & Hers has abandoned plans to sell a compounded version of Novo Nordisk’s Wegovy (semaglutide) pill, though Novo and…
-
FDA targets illegal drug copies amid latest Hims & Hers/Novo Nordisk flashpoint
US Food and Drug Administration (FDA) Commissioner Marty Makary said the agency would target the mass-marketing of unapproved drugs amid…
-
Corxel raises $287m as obesity continues to spark investor interest
Corxel Pharmaceuticals has raised $287m to fund its suite of cardiometabolic assets, signifying that investor appetite for weight loss drug…
-
Drugmakers welcome FDA’s GLP-1RA suicide warning removal request
The US Food and Drug Administration (FDA) has requested that pharma companies marketing glucagon-like peptide-1 receptor agonists (GLP-1RAs) no longer…
-
Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus
Eli Lilly has signed a research and licence agreement with Nimbus Therapeutics, aiming to develop a new oral weight loss…
-
Novo beats Lilly to first FDA-approved GLP-1RA pill for obesity
Novo Nordisk has ushered in a new era of obesity treatment – gaining the first US Food and Drug Administration…
-
Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA
Pfizer has confirmed another push into the obesity market in the form of a licencing deal worth up to approximately…
-
WHO backs use of GLP-1RAs for weight loss despite shortage warning
The World Health Organization (WHO) has endorsed the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the treatment of obesity,…
